A Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final Results

Annals of Thoracic Surgery

Volumn 86, Issue 2, 2008, Pages 383-390

  Pass, Harvey I ^a   Brewer, George J ^b   Dick, Robert ^b   Carbone, Michele ^c   Merajver, Sofia ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; CISPLATIN; GEMCITABINE; PEMETREXED; TETRATHIOMOLYBDIC ACID; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ARTICLE; BEDTIME DOSAGE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; COPPER DEFICIENCY; CYTOREDUCTIVE SURGERY; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; MAINTENANCE THERAPY; MALE; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA MESOTHELIOMA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CERULOPLASMIN; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; MOLYBDENUM; PLEURAL NEOPLASMS; SALVAGE THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47149104324     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2008.03.016     Document Type: Article

References (23)

1. Carbone M., Albelda S.M., Broaddus V.C., et al. Eighth International Mesothelioma Interest Group. Oncogene 26 (2007) 6959-6967
2. Scagliotti G.V., and Selvaggi G. Emerging drugs for mesothelioma. Expert Opin Emerg Drugs 12 (2007) 127-137
3. Richards W.G., Zellos L., Bueno R., et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 24 (2006) 1561-1567
4. Weder W., Stahel R.A., Bernhard J., et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 18 (2007) 1196-1202
5. Flores R.M. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 49 Suppl 1 (2005) S71-S74
6. Utkan G., Yalcin B., Buyukcelik A., and Yalcin S. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma: is it safe?. [Letter]. J Clin Oncol 23 (2005) 655
7. Rice D.C., Stevens C.W., Correa A.M., et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 84 (2007) 1685-1692
8. Stevens C.W., Forster K.M., Smythe W.R., and Rice D. Radiotherapy for mesothelioma. Hematol Oncol Clin North Am 19 (2005) 1099-1115 vii
9. Rusch V.W., Rosenzweig K., Venkatraman E., et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122 (2001) 788-795
10. Carbone M., Albelda S.M., Broaddus V.C., et al. Eighth international mesothelioma interest group. Oncogene 26 (2007) 6959-6967
11. Brewer G.J. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Curr Cancer Drug Targets 5 (2005) 195-202
12. Brewer G.J., Hedera P., Kluin K.J., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60 (2003) 379-385
13. Brewer G.J., Dick R.D., Grover D.K., et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 6 (2000) 1-10
14. Redman B.G., Esper P., Pan Q., et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9 (2003) 1666-1672
15. Catalano A., and Gianni W. Procopio A. Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments. Crit Rev Oncol Hematol 50 (2004) 101-109
16. Adachi Y., Aoki C., Yoshio-Hoshino N., Takayama K., Curiel D.T., and Nishimoto N. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer 119 (2006) 1303-1311
17. Antony V.B., Hott J.W., Godbey S.W., and Holm K. Angiogenesis in mesotheliomas: role of mesothelial cell derived IL-8. Chest 109 Suppl (1996) 21-2S
18. Galffy G., Mohammed K.A., Dowling P.A., Nasreen N., Ward M.J., and Antony V.B. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 59 (1999) 367-371
19. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14 (1996) 1-12
20. Stewart D.J., Martin-Ucar A., Pilling J.E., Edwards J.G., O'Byrne K.J., and Waller D.A. The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg 78 (2004) 245-252
21. Lee T.T., Everett D.L., Shu H.K., et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 124 (2002) 1183-1189
22. Yajnik S., Rosenzweig K.E., Mychalczak B., et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 56 (2003) 1319-1326
23. Zellos L., and Christiani D.C. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 14 (2004) 469-477 viii